Brand Name
Margenza
Generic Name
Margetuximab-Cmkb
View Brand Information FDA approval date: January 15, 2021
Classification: HER2/neu Receptor Antagonist
Form: Injection
What is Margenza (Margetuximab-Cmkb)?
MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [see Dosage and Administration.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment